Follistatin 344 1mg/vial 1 Vial by Bio-Peptide

Usage

1. Pre-reconstitution check: Confirm the lyophilised cake is intact and the vial seal is unbroken; verify HPLC and LAL certificates match the batch number printed on the vial.
2. Prepare reconstitution solution: Draw 1–2 mL of bacteriostatic water into an insulin syringe; select volume based on your target concentration (e.g. 1 mL = 1 mg/mL; 2 mL = 0.5 mg/mL).
3. Reconstitute carefully: Insert the syringe at an angle and direct the water slowly down the inner vial wall — never inject directly onto the peptide cake, as foaming denatures the protein structure.
4. Swirl, do not vortex: Gently rotate the vial between your fingers until the powder fully dissolves; a clear, colourless solution indicates correct reconstitution.
5. Draw your research dose: Use a fresh insulin syringe to withdraw the calculated volume corresponding to your target mcg dose; administer subcutaneously, rotating sites to avoid tissue irritation.
6. Post-use storage: Cap the reconstituted vial, return immediately to 2–8 °C refrigeration, and use within 48–72 hours; discard any unused solution after this window to ensure data integrity and safety.

Warnings

Frequently asked questions

What exactly does Follistatin-344 block in the body and how does that affect muscle tissue?

Follistatin-344 binds myostatin (GDF-8) and activin A — both members of the TGF-β superfamily — preventing them from activating the ActRIIB receptor that suppresses muscle growth. By neutralising these ligands, Follistatin-344 removes the primary molecular brake on satellite cell proliferation and muscle fibre formation, enabling a hyperplastic rather than purely hypertrophic response in preclinical models.

How significant is the muscle growth effect observed with myostatin inhibition in research settings?

Preclinical studies using follistatin overexpression in murine models have documented lean-mass increases of 20–30 %, attributed to satellite cell activation (tracked via MyoD marker expression) and suppression of atrogene signalling (MuRF-1, MAFbx). These gains represent some of the largest pharmacologically induced muscle-mass changes observed in animal models, which is precisely why myostatin inhibition remains a priority research target.

Why are Follistatin-344 and ACE-031 considered experimental and not approved therapeutic compounds?

Neither compound has passed the full clinical trial process required for regulatory approval. Both modulate ActRIIB ligand availability potently enough to raise unresolved safety questions — particularly regarding off-target effects on cardiac muscle, haematopoiesis, and bone mineral density. Phase II trials of ACE-031 in Duchenne muscular dystrophy were suspended partly due to adverse vascular findings, underscoring why Follistatin-344 research must proceed under controlled, monitored conditions.

How should Bio-Peptide Follistatin-344 1mg vial be reconstituted and stored after opening?

Reconstitute the 1 mg lyophilised powder with 1–2 mL of bacteriostatic water using a slow, wall-directed injection to avoid foaming and peptide degradation. Once reconstituted, store the vial at 2–8 °C and use within 48–72 hours for optimal peptide stability. The 1 mg format allows researchers to prepare precise low-concentration solutions suited to micro-dosing protocols, a practical advantage of this entry-level vial size.

Why choose the 1mg/vial format of Follistatin-344 over higher-concentration options for research?

The 1 mg/vial concentration is the lowest available in Bio-Peptide's Follistatin series, making it ideal for pilot studies, dose-response curve work, and reconstitution-volume calibration before scaling. Researchers can prepare solutions ranging from 0.1 mg/mL to 1 mg/mL depending on experimental need, providing flexibility that a fixed high-concentration vial limits. It also reduces waste risk when establishing individual research protocols. (2) angle_used

Manufacturer

Bio-Peptide's origins trace to a gap the founders identified in the European research compound sector: a near-total absence of manufacturers willing to publish independent, third-party quality documentation alongside their products. Rather than scaling volume first and addressing quality infrastructure later, Bio-Peptide inverted that model — commissioning external laboratory verification (HPLC sequence confirmation and LAL endotoxin certification) from the outset and treating those certificates as non-negotiable product deliverables, not optional marketing additions. That founding decision shaped every subsequent operational choice: raw amino-acid sourcing is governed by documented supplier qualification, synthesis batches run under cGMP-aligned process controls, and release is contingent on passing both purity and endotoxin thresholds rather than on production timelines. The result is a manufacturer whose reputation in the research community rests on verifiable data rather than claims alone.